methylprednisolone, prednisone
PreclinicalSmall molecule
Bristol-Myers Squibbmethylprednisolone, prednisone is one of 7 small molecule programs targeting Glomerular Disease. It is currently in Preclinical.
1
Indications
5
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Glomerular Disease
#DrugCompanyPhaseTrials
1Filspari
TTravere Therapeutics, Inc.
Phase 2
Povetacicept
Vertex PharmaceuticalsPhase 2
Vanrafia
NovartisPhase 2
Medrol
PfizerPreclinical
Velcade
SShilpa Grover, MD, MPH
Preclinical
Rayos
RRoxane Laboratories
Preclinical
methylprednisolone, prednisone
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Glomerular Disease1 trial
Kidney Transplant1 trial
Diarrhea1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company